Hutchmed (HCM) said late Thursday it will receive a milestone payment after partner Takeda (TAK) launched Fruzaqla capsules in Japan as a therapy for metastatic colorectal cancer.
The launch follows approval for the manufacturing and sale of Fruzaqla by Japan's Ministry of Health, Labour and Welfare.